Sermorelin UK: Identity, Testing & UK Peptides
Sermorelin UK Explained: Identity, Research History and UK Peptides
Sermorelin is a synthetic 29-amino-acid peptide associated with the growth hormone-releasing hormone receptor. It is often confused with full-length GHRH, modified GRF, CJC-1295, Ipamorelin and growth hormone itself. These are separate molecular identities.
Sermorelin at a Glance
The name Sermorelin refers to a defined peptide. It should not be used as a loose description for every GHRH-related laboratory material.
What Is Sermorelin?
Sermorelin is the recognised name for a synthetic, amidated 29-residue peptide corresponding to the amino-terminal portion of human growth hormone-releasing hormone. 1
It is commonly written as GHRH(1–29)-NH₂ or GRF(1–29)-NH₂.
The numbers 1–29 identify the portion of the longer natural sequence represented by the peptide. The NH₂ notation indicates an amidated carboxyl terminus.
PubChem records the molecular formula of Sermorelin as C149H246N44O42S and its molecular weight as approximately 3357.9 g/mol. 1
In simple language: Sermorelin is a precisely defined 29-residue peptide fragment. Its identity depends on the complete sequence, residue order and terminal amide.
Is Sermorelin Full-Length GHRH?
No. Natural human GHRH is generally described as a longer peptide. Sermorelin represents its amino-terminal 1–29 segment.
The shorter sequence retains a defined receptor identity, but it should not be described as the entire naturally occurring hormone.
Sermorelin corresponds to a particular portion of GHRH. A fragment and the complete natural peptide are related, but they are not identical.
The Sermorelin Amino-Acid Sequence
A scientifically meaningful identity begins with the complete residue order rather than a product abbreviation or vial label.
Tyr–Ala–Asp–Ala–Ile–Phe–Thr–Asn–Ser–Tyr–Arg–Lys–Val–Leu–Gly–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Met–Ser–Arg–NH₂
This sequence is recorded by established chemical and pharmaceutical databases, including PubChem and KEGG. 1 2
Why the Terminal Amide Matters
The final NH₂ is part of the stated chemical structure. A version ending in an unmodified carboxylic acid would have a different molecular identity and mass.
A laboratory document should therefore specify whether the material is amidated rather than showing only the words “Sermorelin peptide”.
Why the Sequence Order Matters
Peptides containing the same amino-acid composition can still be different molecules when their residues appear in a different order.
A stated total of 29 residues does not establish that the material is Sermorelin.
Why Oxidation Requires Attention
Sermorelin contains a methionine residue. Methionine can be relevant when laboratories investigate oxidation-related variants during analytical characterisation or stability work.
This does not mean that every secondary chromatographic peak has the same identity. Peaks require appropriate investigation rather than assumption.
Sermorelin, Sermorelin Acetate and Geref
These terms are connected, but they do not communicate exactly the same information.
Sermorelin
The recognised peptide name referring to GHRH(1–29)-NH₂.
Sermorelin Acetate
A material form in which the peptide is associated with acetate counterions. Documentation should state clearly whether reported quantity relates to the peptide, salt or total material. 3
Geref
A historical medicinal product brand. The existence of an earlier brand does not establish present UK authorisation or validate an unrelated material using that name.
GRF(1–29)-NH₂
Growth hormone-releasing factor is an alternative historical term for growth hormone-releasing hormone.
What Does Acetate Mean on a Certificate?
Many synthetic peptides are isolated in salt forms. The associated counterion contributes to the total material composition.
A certificate should make clear whether a reported quantity represents:
- Net peptide content
- Peptide salt content
- Total dried material
- A nominal filling target
Those measurements should not be treated as interchangeable.
Sermorelin’s Receptor Context
Receptor classification is useful for distinguishing Sermorelin from peptides that are frequently grouped beside it online.
GHRH Receptor
Sermorelin is classified as an agonist of the growth hormone-releasing hormone receptor. 4
Human GHRH
Sermorelin corresponds to the first 29 residues of the longer naturally occurring signalling peptide.
Ipamorelin
Ipamorelin is associated with the ghrelin or growth hormone secretagogue receptor rather than the GHRH receptor.
Human Growth Hormone
Human growth hormone is a much larger protein with a separate molecular identity and receptor target.
Mechanism Is Not a Consumer Outcome Claim
Identifying a receptor target explains molecular classification. It does not establish that an unauthorised online material is safe, suitable, clinically useful or equivalent to a historical medicinal product.
Sermorelin Research and Regulatory History
Historical investigation should be reported accurately without converting past research into a present-day consumer promotion.
Identification of the Active Fragment
Researchers investigated the amino-terminal portion of human growth hormone-releasing factor and established GHRH(1–29)-NH₂ as a defined research peptide.
Controlled Pharmacology and Diagnostic Research
Sermorelin and related GHRH fragments were examined in controlled research settings involving receptor pharmacology, peptide response measurement and diagnostic methodology. 5
Historical research conditions and authorised products should not be conflated with unrelated ecommerce materials.
Geref Products
Sermorelin acetate was historically marketed under the Geref name in certain jurisdictions.
The United States Food and Drug Administration later determined that the relevant discontinued Geref products were not withdrawn for reasons of safety or effectiveness. 6
That administrative finding does not create current UK authorisation and does not approve unrelated compounded or research-labelled materials.
Cancelled Geref Licence
An official MHRA historical licence dataset lists a Geref product containing Sermorelin with the licence status recorded as cancelled. 7
No Current UK Authorisation Identified
The official sources reviewed for this article did not identify a current UK marketing authorisation for a Sermorelin medicinal product.
Businesses should verify the position directly with the MHRA and obtain specialist advice rather than relying on this general editorial summary.
Why Historical Approval Must Be Presented Carefully
Historical authorisation demonstrates that a particular product was assessed within a particular jurisdiction and period.
It does not prove that:
- A current UK marketing authorisation exists
- An online vial is the former branded product
- A new manufacturer uses the historical specification
- A research certificate replaces medicines authorisation
- A product can be promoted to the public
- A historical brand can be copied onto unrelated packaging
Sermorelin Compared with Related Peptides
The table describes molecular and regulatory distinctions. It does not rank substances or recommend one over another.
| Material | General identity | Research receptor | Important distinction |
|---|---|---|---|
| Sermorelin | Amidated 29-residue GHRH fragment | GHRH receptor | Defined as GHRH(1–29)-NH₂ and historically associated with Geref |
| Natural human GHRH | Longer naturally occurring peptide | GHRH receptor | Sermorelin represents only its amino-terminal 1–29 portion |
| Modified GRF(1–29) | Modified 29-residue GHRH-related peptide | GHRH receptor | Contains residue substitutions and should not be labelled as unmodified Sermorelin |
| CJC-1295 | Modified GHRH-related peptide | GHRH receptor | Distinct sequence and design; DAC and non-DAC terminology can introduce further ambiguity |
| Tesamorelin | Modified GHRH analogue | GHRH receptor | Different sequence length and structural modification |
| Ipamorelin | Synthetic pentapeptide | Ghrelin receptor | Different peptide family and receptor pathway |
| GHRP-2 or GHRP-6 | Synthetic secretagogue peptides | Ghrelin receptor | Not GHRH fragments and not forms of Sermorelin |
| Human growth hormone | Large protein hormone | Growth hormone receptor | A separate protein rather than a GHRH receptor ligand |
Sermorelin and Modified GRF(1–29)
Modified GRF(1–29) contains substitutions intended to change properties of the parent 29-residue sequence.
A modified sequence must not be documented as Sermorelin merely because both materials contain 29 residues.
Sermorelin and CJC-1295
CJC-1295 was developed as a distinct GHRH-related analogue. Published research describes albumin-binding versions intended to alter molecular persistence. 8
The terms “CJC without DAC”, “modified GRF” and “Sermorelin” are often used inconsistently by commercial websites. A laboratory should rely on the actual sequence and modification record rather than the headline name.
Sermorelin and Ipamorelin
These materials belong to different peptide families and interact with different receptor systems.
A combined product would contain separate molecular entities. A certificate for each starting material would not by itself establish the composition or homogeneity of a finished blend.
Common Sermorelin Naming Errors
Confused nomenclature can create scientific, analytical and regulatory problems even where no explicit consumer claim is made.
Calling Every GHRH Peptide Sermorelin
CJC-1295, modified GRF, Tesamorelin and full-length GHRH are separate molecular identities.
Omitting the Terminal Amide
GHRH(1–29) and GHRH(1–29)-NH₂ do not provide exactly the same structural description.
Ignoring Acetate Content
Peptide quantity, acetate content, water and total dried material should not be treated as one measurement.
Using Geref as Proof of Approval
A former brand name does not demonstrate current UK authorisation or establish the provenance of a new product.
Calling HPLC an Identity Test
Chromatographic purity and molecular identity are separate analytical questions.
Using a Code Instead of a Sequence
A supplier code or vial abbreviation cannot establish residue order, terminal form or salt identity.
Sermorelin and UK Regulation
Legal classification depends on the complete product presentation, not simply the wording printed beneath the product name.
Identity
Authorities may consider the substance, salt form and known pharmacological characteristics.
Claims
Explicit and implied statements can influence medicinal classification.
Presentation
Imagery, website categories, testimonials and associated equipment can affect the overall impression.
Likely Use
Regulators may consider how an ordinary visitor is likely to understand and use the material.
The MHRA Medicines Boundary
The MHRA considers both presentation and function when determining whether a product falls within the legal definition of a medicinal product. 9
Relevant features can include:
- The substance name
- The known pharmacological characteristics
- Explicit claims
- Claims implied through surrounding text
- Product imagery
- Consumer reviews
- Website categories
- Instructions and calculators
- Associated administration equipment
- Links leading directly to supply
Why “Research Use Only” Is Not Decisive
Research-use wording can describe a genuine laboratory purpose, but it does not override contradictory evidence elsewhere on the page.
A research label is weakened where the wider presentation contains:
- Personal-use instructions
- Consumer outcome promises
- Transformation imagery
- Testimonials describing physical changes
- Administration demonstrations
- Direct comparison with prescription medicines
- Consumer bundles or starter kits
Advertising Without a Marketing Authorisation
Regulation 279 of the Human Medicines Regulations restricts the publication of advertisements for medicinal products that do not hold the required authorisation, registration or certificate. 10
CAP Code Section 12 states that marketing communications for an unlicensed product must not make medicinal or therapeutic claims unless authorised by the MHRA. 11
This article therefore limits itself to identity, historical records, analytical concepts and regulation.
Editorial Reporting and Commercial Promotion
A neutral scientific article is easier to distinguish from promotion where it contains:
- No price or stock information
- No purchase or enquiry button
- No direct product-page link
- No consumer outcome claims
- No dosing or administration instructions
- No testimonials
- No product comparison designed to encourage selection
- Balanced official and scientific sources
Chemical and Workplace Duties
Where a peptide is lawfully handled as a laboratory substance, separate chemical and workplace requirements may also require assessment.
These can include UK REACH, classification and labelling obligations, safety-data communication, COSHH assessment, controlled storage and documented disposal. 12 13
A Safety Data Sheet is a source of information. It is not a substitute for the institution’s own risk assessment.
Sermorelin and Anti-Doping Rules
The World Anti-Doping Agency’s 2026 Prohibited List expressly names Sermorelin among growth hormone-releasing hormone analogues. 14
This status applies independently from questions about medicines authorisation, chemical supply or laboratory classification.
A research label, historical medicine name or supplier statement does not remove anti-doping responsibility.
Athletes, coaches, laboratories and support personnel should use official anti-doping resources applicable to their sport and jurisdiction.
How Is Sermorelin Identified in Laboratory Research?
Laboratory identity requires more than a product name and a single percentage printed on a certificate.
HPLC can separate detectable components and report the relative peak area associated with the principal chromatographic component.
Mass analysis can assess whether observed molecular information is consistent with the expected amidated 29-residue peptide.
Peptide mapping or tandem mass-spectrometric methods may provide additional confidence concerning residue order.
Acetate and other counterions may require separate measurement where material composition or net peptide content matters.
Residual water can contribute to total material mass without being part of the peptide molecule.
Analytical reports should identify the exact batch received rather than a generic example or unrelated historical lot.
What Should a Sermorelin Certificate Identify?
- The complete name Sermorelin
- The description GHRH(1–29)-NH₂ where appropriate
- The complete 29-residue sequence
- The terminal amide
- The stated salt or counterion form
- The expected molecular mass
- The observed identity result
- The chromatographic method and result
- The batch or lot number
- The analysis date
- The issuing laboratory or manufacturer
- A traceable report identifier
- The basis of any quantity or assay statement
What HPLC Purity Does Not Establish
A high chromatographic area percentage does not automatically prove:
- That the principal peak is Sermorelin
- That the residue order is correct
- That the terminal amide is present
- That the material has the claimed net peptide content
- That acetate and water have been quantified
- That the material is sterile
- That microbiological attributes have been assessed
- That the material matches a historical medicinal product
- That the material is suitable for administration
Why 99 Per Cent Can Be Misread
An HPLC area-purity figure generally describes the proportion of detected chromatographic peak area assigned to the principal peak under the stated analytical method.
It is not necessarily the percentage of the total physical contents represented by net Sermorelin peptide.
Identity, chromatographic purity, net peptide content, salt content, water, sterility and legal status are separate questions.
Due Diligence for Authorised Institutional Research
This section is not a consumer supplier guide. It outlines governance questions for appropriately authorised laboratories and institutions.
Document the Research Purpose
Record why Sermorelin is required and how it relates to an approved programme of work.
Review the Legal Position
Assess medicines, chemical, import, ethical and institutional requirements before acquisition.
Verify the Legal Entities
Identify the manufacturer, importer, distributor and responsible quality contacts.
Confirm the Sequence
Require the complete residue order and terminal-amide specification.
Confirm the Material Form
Establish whether the material is Sermorelin free peptide, Sermorelin acetate or another stated form.
Match the Certificate to the Batch
Ensure the report corresponds to the lot physically received.
Review Orthogonal Evidence
Consider identity data alongside chromatographic purity rather than relying on a single method.
Understand the Quantity Basis
Determine whether the stated amount represents net peptide, salt, dried material or nominal fill.
Complete a COSHH Assessment
Assess handling, exposure, controls, storage, emergency procedures and disposal.
Control Access
Store research material under appropriate institutional custody and access restrictions.
Maintain Traceability
Retain appropriate receipt, use, transfer and disposal records.
Consider Anti-Doping Risk
Organisations connected with sport should account for Sermorelin’s expressly prohibited status.
Lower-Risk Editorial Cover Design
A scientific cover should communicate identity without resembling a consumer product advertisement.
Suitable visual elements include:
- An abstract 29-residue peptide chain
- The neutral text “Sermorelin”
- The notation GHRH(1–29)-NH₂
- A generic laboratory vial without quantity or dose
- A chromatogram or mass-spectrum motif
- The statement “Laboratory identity guide”
- The statement “UK regulatory overview”
Avoid:
- Milligram quantities
- Administration equipment
- Human-body diagrams suggesting outcomes
- Transformation imagery
- Claims about physical or psychological changes
- The words treatment, therapy, prescription or approved
- Badges implying clinical endorsement
- Product-style batch labels
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileFrequently Asked Questions About Sermorelin UK
Neutral answers concerning identity, regulation and analytical documentation.
What is Sermorelin?
Sermorelin is an amidated 29-amino-acid peptide corresponding to the amino-terminal 1–29 segment of human growth hormone-releasing hormone.
What does GHRH(1–29)-NH₂ mean?
It identifies residues 1 through 29 of the GHRH sequence and states that the peptide has an amidated terminal group.
Is Sermorelin the same as full-length GHRH?
No. Sermorelin represents a defined amino-terminal fragment rather than the complete naturally occurring peptide.
Is Sermorelin acetate a different peptide?
The peptide sequence is Sermorelin, while acetate describes an associated salt or counterion form. The distinction matters when interpreting material composition and quantity.
Is Geref the same as every Sermorelin product?
No. Geref was a historical brand for particular authorised products. An unrelated material bearing the Sermorelin name is not automatically Geref or equivalent to it.
Is Sermorelin the same as modified GRF(1–29)?
No. Modified GRF contains residue substitutions and has a different molecular identity from unmodified Sermorelin.
Is Sermorelin the same as CJC-1295?
No. CJC-1295 is a separately designed GHRH-related analogue with different structural features.
Is Sermorelin the same as Ipamorelin?
No. Sermorelin is a 29-residue GHRH-related peptide. Ipamorelin is a five-residue peptide associated with the ghrelin receptor pathway.
Does Sermorelin currently have UK marketing authorisation?
The official sources reviewed for this article did not identify a current UK marketing authorisation. An MHRA historical record lists a Geref Sermorelin licence as cancelled.
Does a former overseas approval create UK approval?
No. Authorisation is product-specific, jurisdiction-specific and time-specific.
Can a Research Use Only label settle the legal position?
No. Regulators may consider the substance, claims, imagery, instructions, commercial context and likely intended use.
Is Sermorelin prohibited in competitive sport?
Yes. Sermorelin is expressly named on the World Anti-Doping Agency’s 2026 Prohibited List.
Does HPLC prove that a sample is Sermorelin?
Not by itself. HPLC provides chromatographic information. Molecular identity requires appropriate supporting analysis.
What is important on a Sermorelin COA?
Important details include the complete sequence, terminal amide, material form, expected and observed identity information, chromatographic result, batch number and analysis date.
Does 99 per cent HPLC purity mean 99 per cent net peptide?
Not necessarily. Chromatographic area purity and net peptide content are different measurements.
Why does this article contain no consumer buying guide?
A public supplier-selection guide could encourage acquisition of a pharmacologically active material. Procurement discussion is therefore limited to governed institutional research.
Does this article recommend Sermorelin?
No. It provides information concerning molecular identity, historical records, regulation, analytical testing and anti-doping rules.
The Balanced View
Sermorelin is a well-defined 29-residue peptide with a documented scientific and historical pharmaceutical record.
That history does not make every material bearing the name equivalent to a former authorised product.
The most useful distinctions are:
- Sermorelin is GHRH(1–29)-NH₂ rather than full-length natural GHRH.
- Sermorelin acetate describes a salt form and requires clear quantity reporting.
- Modified GRF, CJC-1295, Tesamorelin and Ipamorelin are separate molecular identities.
- Historical Geref products do not establish current UK authorisation.
- A product name and HPLC percentage do not establish complete identity.
- Research-use wording does not override contradictory commercial presentation.
- Sermorelin is expressly prohibited under current anti-doping rules.
Responsible Sermorelin reporting begins with the exact sequence and current regulatory position, not promises attached to a product name.
Scientific and Official Sources
- PubChem: Sermorelin molecular identity, formula and structure
- KEGG Drug: Sermorelin sequence and molecular record
- PubChem: Sermorelin acetate
- ChEMBL: Sermorelin acetate and GHRH receptor agonist classification
- Prakash and Goa: Review of Sermorelin’s diagnostic and historical research use
- United States FDA determination concerning discontinued Geref products
- MHRA historical product licence dataset listing Geref Sermorelin as cancelled
- Jetté and colleagues: Identification and characterisation of CJC-1295 as a distinct GHRH analogue
- MHRA: Borderline products and how to tell if a product is a medicine
- Human Medicines Regulations 2012: Regulation 279
- CAP Code Section 12: Medicines and health-related products
- Health and Safety Executive: UK REACH
- Health and Safety Executive: Safety Data Sheets and COSHH
- World Anti-Doping Agency: 2026 Prohibited List
